title: Effects of pitavastatin and atorvastatin on lipoprotein oxidation biomarkers in patients with dyslipidemia.
abstract: OBJECTIVE
  The effects of potent statins on oxidized lipoprotein biomarkers are not well defined.
  
  
  RESULTS
  The VISION (Value of oxIdant lipid lowering effect by Statin InterventiON in hypercholesterolemia) Trial randomized patients with hypercholesterolemia to 12-week administration of pitavastatin 2 mg/day (n = 21) or atorvastatin 10 mg/day (n = 21) and a variety of lipoprotein oxidative biomarkers were measured. Between-group analysis did not reveal any differences except in the ratio of malondialdehyde (MDA)-LDL over apolipoprotein B-100 (MDA-LDL/apoB) in pitavastatin vs. atorvastatin group (-13% vs. -0.7%, p = 0.04). Within-group changes from baseline to 12-week revealed significant increases in OxPL/apoB and reductions in small-dense LDL, MDA-LDL, and lipoprotein-associated phospholipase A(2) measured on circulating apoB particles (Lp-PLA(2)/apoB) in both groups and significant reductions in OxPL/apoAI in the atorvastatin group.
  
  
  CONCLUSIONS
  The VISION study describes the first comparison on lipoprotein oxidation biomarkers between pitavastatin and atorvastatin and suggests diverse effects on lipoprotein oxidation markers in patients with hypercholesterolemia.
authors.affiliation: Department of Laboratory Medicine, Jikei University Kashiwa Hospital, Chiba, Japan; Department of General Medicine, Jikei University Kashiwa Hospital, Chiba, Japan. hyoshida@jikei.ac.jp
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Yoshida
authors.forename: Toru
authors.initials: T
authors.lastname: Shoda
authors.forename: Hidekatsu
authors.initials: H
authors.lastname: Yanai
authors.forename: Katsunori
authors.initials: K
authors.lastname: Ikewaki
authors.forename: Hideaki
authors.initials: H
authors.lastname: Kurata
authors.forename: Kumie
authors.initials: K
authors.lastname: Ito
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Furutani
authors.forename: Norio
authors.initials: N
authors.lastname: Tada
authors.forename: Joseph L
authors.initials: JL
authors.lastname: Witztum
authors.forename: Sotirios
authors.initials: S
authors.lastname: Tsimikas
mesh_terms: D000069059:Atorvastatin; D015415:Biomarkers / Q000097:blood; D005260:Female; D006538:Heptanoic Acids / Q000494:pharmacology*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology*; D006937:Hypercholesterolemia / Q000097:blood / Q000378:metabolism*; D008074:Lipoproteins / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D010084:Oxidation-Reduction; D011446:Prospective Studies; D011758:Pyrroles / Q000494:pharmacology*; D011804:Quinolines / Q000494:pharmacology*
chemical_list: D015415:Biomarkers; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008074:Lipoproteins; D011758:Pyrroles; D011804:Quinolines; D000069059:Atorvastatin; C108475:pitavastatin